3,157 Shares in Krystal Biotech, Inc. $KRYS Bought by Assetmark Inc.

Assetmark Inc. acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,157 shares of the company’s stock, valued at approximately $816,000.

Several other large investors have also bought and sold shares of the business. Soleus Capital Management L.P. raised its stake in Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Norges Bank acquired a new stake in shares of Krystal Biotech in the 4th quarter valued at approximately $70,159,000. William Blair Investment Management LLC boosted its stake in shares of Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Krystal Biotech by 2,078.9% during the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after purchasing an additional 209,369 shares during the last quarter. Finally, UBS Group AG grew its holdings in shares of Krystal Biotech by 970.8% during the 4th quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after purchasing an additional 177,922 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KRYS. TD Cowen upped their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. Bank of America boosted their target price on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Citigroup upped their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a report on Monday, July 13th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Trading Up 2.3%

Shares of KRYS stock opened at $335.19 on Friday. The firm has a market capitalization of $9.88 billion, a price-to-earnings ratio of 44.81 and a beta of 0.50. The business’s 50-day moving average price is $333.77 and its 200-day moving average price is $292.52. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 7.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock valued at $8,243,923 in the last ninety days. Insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.